Martin G. Cook

Martin G. Cook

Auto-generated profile, based on publicly available information

Martin G. Cook

Histopathology, Royal Surrey County Hospital, Guildford, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
MCMartin G. Cook
Martin G. Cook
DMDaniela Massi
Daniela Massi
ASAnna Szumera-Cieckiewicz
Anna Szumera-Cieckiewicz
JOJoost Van Den Oord
Joost Van Den Oord
WBWilleke Blokx
Willeke Blokx
AAAlexander C.J. van Akkooi
Alexander C.J. van Akkooi

30 May 2008 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
MCM G Cook
M G Cook
SPS Di Palma
S Di Palma
As a concept sentinel lymph node biopsy seems attractive in that it attempts to identify the first lymph node, rather than the nearest node, draining a particular anatomic area where a tumour has arisen. Pathological assessment can then indicate whether metastases are present and the procedure is either a strong prognostic indicator or possibly therapeutic in itself. These comments apply to any tumour type, but with melanoma the pathological procedure is more problematic and any benefits above prognosis and staging are not universally accepted. The procedure does give accurate staging without the extra morbidity of regional node dissection and many patients gain psychological support from the information gained.

25 July 2017 in Histopathology
Verified
Journal Article
Open access
PDF file
MCMartin G Cook
Martin G Cook
DMDaniela Massi
Daniela Massi
WBWilleke Blokx
Willeke Blokx
JOJoost Van Den Oord
Joost Van Den Oord
SKSenada Koljenović
Senada Koljenović
MMMartin C Mihm
Martin C Mihm
Aims: Because the term ‘naevoid melanoma’ has variable clinical and pathological interpretations, we aimed to clarify the features of melanomas referred to as naevoid.Methods and results: A review was undertaken of 102 melanomas diagnosed histopathologically as naevoid melanomas and ascertained by European Organization for Research and Treatment of Cancer Melanoma Group Subcommittee pathologists from their records. We found these could be classified morphologically into three groups. Thirteen melanomas were overlying genuine naevi and were therefore excluded. Of the 89 melanomas considered to be naevoid, 11 presented clinically as exophytic papillomatous nodules with little junctional component and composed of small atypical cells showing numerous mitoses and no change with depth; we termed these ‘papillomatous naevoid’ melanomas. The other 78 were flat or only slightly raised, and had a superficial spreading melanoma‐like component with maturation to a small cell, but still an atypical, dermal component; we termed these ‘maturing naevoid’ melanomas. We showed that papillomatous and maturing naevoid melanomas also have differing immunochemical profiles. Preliminary clinical follow‐up suggested different outcomes for these two naevoid melanoma types.Conclusions: Melanomas that have been classified as naevoid melanomas comprise two types with distinct clinical, histopathological and immunohistochemical features that may also be prognostically significant.

19 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMAntonella Manca
Antonella Manca
MSMaria Cristina Sini
Maria Cristina Sini
ACAnna Maria Cesinaro
Anna Maria Cesinaro
FPFrancesca Portelli
Francesca Portelli
CUCarmelo Urso
Carmelo Urso
DMDaniela Massi
Daniela Massi
Deep penetrating nevi (DPNs) are rare melanocytic neoplasms consisting of pigmented spindled or epithelioid melanocytes with a distinctive wedge-shaped configuration showing activation of the WNT pathway, with unusual cyto-architectural features. It is unclear whether they show a distinct genomic profile associated with a diverse metastatic potential. We describe herein a cohort of 21 atypical DPNs analyzed by next-generation sequencing using the Ion AmpliSeq™ Comprehensive Cancer Panel. We found that β-catenin exon 3 was mutated in 95% and MAP kinase pathway genes in 71% of the cases. Less frequent mutations were observed in HRAS (19%) and MAP2K1 (24%). Isocitrate dehydrogenases 1 (IDH1) mutations, including R132C, V178I, and S278L, were identified in 38% of cases and co-existed with BRAF/HRAS mutations. The only case with progressive nodal disease carried alterations in the β-catenin pathway and mutations in IDH1 and NRAS (codon 61). By a comprehensive mutation analysis, we found low genetic heterogeneity and a lack of significant associations between specific gene mutations and histopathological features, despite atypical features. Whether the acquisition of an NRAS or IDH1 mutation in an atypical DPN may represent a molecular evolution implying a pathway to melanoma progression should be confirmed in a larger series.

20 July 2021 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
MCMartin G. Cook
Martin G. Cook
BPBarry W. E. M. Powell
Barry W. E. M. Powell
MGMegan E. Grant
Megan E. Grant
AGAdele C. Green
Adele C. Green
Desmoplastic melanoma commonly occurs on the head and neck in a pure form, but occasionally, it occurs in a mixed tumor with another type, usually superficial spreading melanoma (SSM), and rarely as a metastasis from a primary SSM. We report here a primary SSM on the leg of a 32-year-old male which metastasised to lymph nodes, and 10 years later recurred at the primary site initially with mixed features but evolving to resemble a uniformly desmoplastic, deeply invasive melanoma. This unusual case has implications for clinical management and is additionally notable for its reversal in behavior, from metastatic to local infiltrative type, correlating with the change in morphology.